Kahn Swick & Foti, LLC Investigates Officers and Directors of Lululemon Athletica Inc. for Potential Wrongdoing
Investors who purchased shares of ChemoCentryx, Inc. between November 26, 2019, and May 6, 2021, may be eligible to participate in a class action lawsuit filed against the company. The lawsuit alleges that ChemoCentryx made false and misleading statements about its drug candidate Avacopan, which is intended for the treatment of ANCA-associated vasculitis.
According to the lawsuit, ChemoCentryx failed to disclose the full extent of the drug’s toxicities and risks, leading investors to believe that Avacopan was safer than it actually was. When the truth about the drug’s risks became known, ChemoCentryx’s stock price plummeted, causing financial harm to investors.
If you purchased ChemoCentryx shares during the specified time period and suffered financial losses as a result, you may be entitled to seek compensation. It is important to contact legal counsel as soon as possible to learn more about your rights and options in this class action lawsuit.
The deadline to seek appointment as lead plaintiff in this case is July 6, 2021. Lead plaintiff status is not required to participate in any recovery, and investors can still be represented even if they choose not to be lead plaintiff.
If you have any information about this case or would like to learn more about how to participate, do not hesitate to reach out to the law firm handling this class action lawsuit. They can provide you with the necessary information and guidance to help you understand your legal rights and options.
